Article
Immunology
Glaivy Batsuli, Jasmine Ito, Elizabeth S. York, Courtney Cox, Wallace Baldwin, Surinder Gill, Pete Lollar, Shannon L. Meeks
Summary: This study analyzed the internalization of FVIII complexed with epitope-mapped FVIII-specific IgG monoclonal antibodies by murine bone marrow-derived dendritic cells (BMDCs) in vitro, as well as the antibody development in hemophilia A (FVIII-/-) mice injected with FVIII-IC over time. The results showed that certain FVIII-IC subsets modulate the humoral response to FVIII in an epitope-dependent manner.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Medicine, Research & Experimental
Bhavya S. Doshi, Jyoti Rana, Giancarlo Castaman, Mostafa A. Shaheen, Radoslaw Kaczmarek, John S. S. Butterfield, Shannon L. Meeks, Cindy Leissinger, Moanaro Biswas, Valder R. Arruda
Summary: Inhibitors of factor VIII (FVIII) in hemophilia A are a challenging complication of FVIII protein replacement therapy. Research suggests that BAFF may play a role in regulating the generation and maintenance of FVIII inhibitors, and anti-BAFF therapy could prevent the formation of inhibitors. Combination therapy with anti-CD20 and anti-BAFF antibodies shows promise in significantly reducing FVIII inhibitors.
JOURNAL OF CLINICAL INVESTIGATION
(2021)
Article
Multidisciplinary Sciences
Tiago J. S. Lopes, Ricardo Rios, Tatiane Nogueira, Rodrigo F. Mello
Summary: This study investigated the pathogenesis of hemophilia A by creating a residue interaction network, revealing important properties related to disease severity. The properties derived from the network were found to be in close agreement with in vitro and clinical reports, indicating that the detailed map of the FVIII protein accurately captures its biological properties.
SCIENTIFIC REPORTS
(2021)
Article
Hematology
Kuniyoshi Mizumachi, Yuto Nakajima, Naruto Shimonishi, Shoko Furukawa, Kenichi Ogiwara, Masahiro Takeyama, Keiji Nogami
Summary: Hybrid FVIII proteins containing porcine FVIII A2 and/or C2 domain(s) can avoid neutralization and may support effective therapy in patients with congenital haemophilia A and inhibitor antibodies.
Review
Oncology
Yanjie Huang, Mengzhen Jia, Xiaoqing Yang, Hongyan Han, Gailing Hou, Liangliang Bi, Yueli Yang, Ruoqi Zhang, Xueru Zhao, Chaoqun Peng, Xinshou Ouyang
Summary: ANXA2 is widely used as a marker in various tumors. It plays a role in tumorigenesis and immune response by regulating multiple signal pathways. It is involved in tumor cell invasion and metastasis, angiogenesis, and the expression of inflammatory factors. It also mediates immune response through its interaction with pathogens and antibodies.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Fisheries
Junrong Li, Liqun Wang, Xinyue Zhang, Xiaozhi Wen, Xinyan Wei, Qiwei Qin, Shaowen Wang
Summary: This study identified and characterized AnxA2 (EcAnxA2) in Epinephelus coioides and investigated its role in RGNNV infection. EcAnxA2 was widely expressed in different tissues and its expression was significantly increased after RGNNV infection. Overexpression of EcAnxA2 enhanced RGNNV infection, while knockdown of EcAnxA2 reduced infection. EcAnxA2 also modulated the host immune response by regulating the transcription of interferon-related and inflammatory factors. These findings provide new insights into the role of AnxA2 in fish during virus infection.
FISH & SHELLFISH IMMUNOLOGY
(2023)
Article
Immunology
Carina Saggau, Gabriela Rios Martini, Elisa Rosati, Silja Meise, Berith Messner, Ann-Kristin Kamps, Nicole Bekel, Johannes Gigla, Ruben Rose, Mathias Voss, Ulf M. Geisen, Hayley M. Reid, Melike Sumbul, Florian Tran, Dennis K. Berner, Yascha Khodamoradi, Maria J. G. T. Vehreschild, Oliver Cornely, Philipp Koehler, Andi Krumbholz, Helmut Fickenscher, Oliver Kreuzer, Claudia Schreiber, Andre Franke, Stefan Schreiber, Bimba Hoyer, Alexander Scheffold, Petra Bacher
Summary: This study reveals the heterogeneity of immune response and age-dependent decline in immune response quality caused by SARS-CoV-2 infection and vaccination. The pre-exposure T cell repertoire is found to be correlated with immune response quality, with high-quality responses depending on intact naive repertoire and exclusion of pre-existing memory T cells. In elderly individuals, T cell expansion from both compartments is severely compromised.
Article
Hematology
Amber Vander Kooi, Shuaishuai Wang, Meng-Ni Fan, Alex Chen, Junping Zhang, Chun-Yu Chen, Xiaohe Cai, Barbara A. Konkle, Weidong Xiao, Lei Li, Carol H. Miao
Summary: The N-glycosylation of FVIII has a significant impact on its immunogenicity, as shown in this study. Gene mutations were introduced to eliminate glycosylation at potential sites, and it was found that FVIII activity remained stable while immune responses varied. A specific glycopeptide epitope surrounding one of the glycosylation sites was identified and characterized for its activation of T cells.
Article
Oncology
Minsuk Kwon, Minae An, Samuel J. Klempner, Hyuk Lee, Kyoung-Mee Kim, Jason K. Sa, Hee Jin Cho, Jung Yong Hong, Taehyang Lee, Yang Won Min, Tae Jun Kim, Byung-Hoon Min, Woong-Yang Park, Won Ki Kang, Kyu-Tae Kim, Seung Tae Kim, Jeeyun Lee
Summary: The study shows that patients with microsatellite instability and elevated mutational burden in gastric cancer are associated with clinical response to anti-PD-1 antibodies. By combining whole-exome sequencing with single-cell RNA sequencing, dynamic tumor evolution with collapse of mutational architecture in responders is identified. Diversity in T-cell receptor repertoire is linked to better response to pembrolizumab.
Article
Multidisciplinary Sciences
Matthew T. Henke, Eric M. Brown, Chelsi D. Cassilly, Hera Vlamakis, Ramnik J. Xavier, Jon Clardy
Summary: Research has shown that some isolates of R. gnavus produce a capsular polysaccharide that promotes tolerogenic immune responses, while isolates lacking a capsule trigger robust proinflammatory responses. In mouse experiments, it was also found that mice colonized with an isolate of R. gnavus lacking a capsule showed increased gut inflammation.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Article
Biology
Waleed H. Mahallawi, Talal M. Aljeraisi
Summary: COVID-19 is still considered a global pandemic, with efforts being made to understand the pathogenicity of the novel virus and develop therapeutics and vaccines. A successful in vitro cell culture model was used to evaluate humoral immune response to the SARS-CoV-2-S protein.
SAUDI JOURNAL OF BIOLOGICAL SCIENCES
(2021)
Article
Biochemistry & Molecular Biology
Masahiro Takeyama, Shoko Furukawa, Kana Sasai, Kaoru Horiuchi, Keiji Nogami
Summary: The study aims to investigate the molecular interactions of FIXa in the clustered acidic sites of FVIII. The results show that the clustered acidic residues E1793/E1794/D1795 play a crucial role in the interaction between FVIII and FIXa.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
(2023)
Article
Biochemistry & Molecular Biology
Zeshuai Wang, Zhisheng Wu, Hao Wang, Ruoqing Feng, Guanlin Wang, Muxi Li, Shuang-Yin Wang, Xiaoyan Chen, Yiyi Su, Jun Wang, Weiwen Zhang, Yuzhou Bao, Zhenwei Lan, Zhuo Song, Yiheng Wang, Xianyang Luo, Lingyu Zhao, Anli Hou, Shuye Tian, Hongliang Gao, Wenbin Miao, Yingyu Liu, Huilin Wang, Cui Yin, Zhi-Liang Ji, Mingqian Feng, Hongkun Liu, Lianghui Diao, Ido Amit, Yun Chen, Yong Zeng, Florent Ginhoux, Xueqing Wu, Yuanfang Zhu, Hanjie Li
Summary: Macrophages in human development exhibit diversity and developmental dynamics. The study identifies the presence of microglia-like cells in the fetal epidermis and proangiogenic macrophages around fetal organs.
Article
Hematology
Josse van Galen, Nadia Freato, Malgorzata A. Przeradzka, Eduard H. T. M. Ebberink, Mariette Boon-Spijker, Carmen van der Zwaan, Maartje van den Biggelaar, Alexander B. Meijer
Summary: HDX-MS analysis showed how FIXa alters the structure of the Leu631-Tyr637 region in FVIIIa, thereby regulating the cofactor function of FVIII.
THROMBOSIS AND HAEMOSTASIS
(2021)
Article
Hematology
Yuto Nakajima, Hiroaki Minami, Keiji Nogami
Summary: Studies suggest that certain residues in the A3 acidic region of FVIII play a role in thrombin activation through cleavage at Arg (1689).
THROMBOSIS AND HAEMOSTASIS
(2021)
Article
Hematology
Jordan C. Ciciliano, Yumiko Sakurai, David R. Myers, Meredith E. Fay, Beatrice Hechler, Shannon Meeks, Renhao Li, Brandon Dixon, L. Andrew Lyon, Christian Gachet, Wilbur A. Lam
Review
Hematology
L. A. Valentino, C. L. Kempton, R. Kruse-Jarres, P. Mathew, S. L. Meeks, U. M. Reiss
Article
Hematology
Joshua Eubanks, W. Hunter Baldwin, Rebecca Markovitz, Ernest T. Parker, Courtney Cox, Christine L. Kempton, Shannon L. Meeks
Article
Biotechnology & Applied Microbiology
Philip M. Zakas, Harrison C. Brown, Kristopher Knight, Shannon L. Meeks, H. Trent Spencer, Eric A. Gaucher, Christopher B. Doering
NATURE BIOTECHNOLOGY
(2017)
Article
Hematology
G. Batsuli, J. Ito, R. Mercer, W. H. Baldwin, C. Cox, E. T. Parker, J. F. Healey, P. Lollar, S. L. Meeks
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2018)
Article
Hematology
Phuong-Cac T. Nguyen, Kenneth B. Lewis, Ruth A. Ettinger, Jason T. Schuman, Jasper C. Lin, John F. Healey, Shannon L. Meeks, Pete Lollar, Kathleen P. Pratt
Review
Hematology
Christine L. Kempton, Shannon L. Meeks
Letter
Hematology
D. Q. Tran, R. D. Harvey, S. L. Meeks, R. Chapman, C. L. Kempton
Article
Hematology
P. M. Zakas, K. Vanijcharoenkarn, R. C. Markovitz, S. L. Meeks, C. B. Doering
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2015)
Article
Multidisciplinary Sciences
Caileen M. Brison, Steven M. Mullen, Michelle E. Wuerth, Kira Podolsky, Matthew Cook, Jacob A. Herman, Justin D. Walter, Shannon L. Meeks, P. Clint Spiegel
Review
Hematology
Shannon L. Meeks, Sebastien Lacroix-Desmazes
Article
Medicine, Research & Experimental
Bhavya S. Doshi, Jyoti Rana, Giancarlo Castaman, Mostafa A. Shaheen, Radoslaw Kaczmarek, John S. S. Butterfield, Shannon L. Meeks, Cindy Leissinger, Moanaro Biswas, Valder R. Arruda
Summary: Inhibitors of factor VIII (FVIII) in hemophilia A are a challenging complication of FVIII protein replacement therapy. Research suggests that BAFF may play a role in regulating the generation and maintenance of FVIII inhibitors, and anti-BAFF therapy could prevent the formation of inhibitors. Combination therapy with anti-CD20 and anti-BAFF antibodies shows promise in significantly reducing FVIII inhibitors.
JOURNAL OF CLINICAL INVESTIGATION
(2021)
Article
Hematology
Connie M. Arthur, Patricia E. Zerra, Sooncheon Shin, Jianmei Wang, Xeuzheng Song, Christopher B. Doering, Pete Lollar, Shannon Meeks, Sean R. Stowell
Summary: Recombinant factor VIII (FVIII) products are crucial for the treatment of hemophilia A, but the development of antibodies against FVIII can limit its effectiveness. This study shows that the source of the recombinant FVIII product can influence the development of antibodies, with BHK-derived products displaying greater immunogenicity. The higher levels of nonhuman carbohydrate alpha Gal on BHK-derived FVIII suggest that it may contribute to the formation of anti-FVIII antibodies.
Article
Medicine, General & Internal
Birgit M. Reipert, Christoph J. Hofbauer, Bagirath Gangadharan, Verena Berg, Elizabeth Donnachie, Shannon Meeks, Maria Elisa Mancuso, Joel Bowen, Deborah L. Brown
Summary: Hemophilia A is a rare congenital bleeding disorder caused by a deficiency of functional coagulation factor VIII (FVIII). FVIII replacement therapies commonly lead to the development of neutralizing antibodies against FVIII, but the reasons behind this phenomenon remain unclear. This study aimed to develop training and qualification test procedures for local operators in Hemophilia Treatment Centers to generate reliable data on antigen-induced gene expression signatures in peripheral blood mononuclear cells (PBMC) obtained from small blood volumes. The model antigen used in this study was Cytomegalovirus (CMV) phosphoprotein (pp) 65. A total of 39 operators from 15 clinical sites were trained and qualified, with 31 passing the qualification on the first attempt and eight passing on the second attempt.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Hematology
Glaivy Batsuli, Amanda Greene, Shannon L. Meeks, Robert F. Sidonio
Summary: The majority of hemophilia A patients who undergo ITI successfully achieve tolerance and transition to emicizumab, with most of them maintaining negative inhibitor titers. However, ongoing monitoring of inhibitors and careful selection of factor products are still recommended.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS
(2021)